|Awarded On||August 20, 2014|
|Title||New Therapeutic Strategies for Metastatic Melanoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Kevin N Dalby|
Melanoma is a deadly form of skin cancer killing approximately ten thousand Americans per year, with a disproportionate number residing in Texas. Patients with melanoma have a poor prognosis, because while current targeted therapies are initially effective against the most common forms of melanoma containing a specific type of mutant BRAF kinase, their efficacy is limited by the near universal acquisition of resistance and resulting progressive disease. Furthermore, no effective targeted therapy exists for patients with melanomas driven by mutations in other genes, such as NRAS, which also have a substantially worse prognosis. Our multi-disciplinary team at UT Austin, and MD Anderson perform...